Furthermore, Indivior’s extended-release buprenorphine, SUBLOCADE, has shown efficacy in reducing opioid use in patients with opioid use disorder, as demonstrated in a recent clinical trial. The trial ...

New York City-based Newtyn Management increased its stake in Indivior by nearly 1.6 million shares in the third quarter, resulting in a net position change of $62.8 million. The transaction represents ...

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...

The company raised its 2025 guidance, with Ciaffoni indicating, "We now expect total net revenue in 2025 to be up versus 2024, driven by SUBLOCADE growth of 10% at the midpoint." Preblick stated, "Our ...

Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. 10 stocks ...

Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. Shares in ...

Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. According ...

Squarespace wants you to build a website with AI. Its Blueprint AI Builder feature began life as a guided website design system in 2023, but, like many things these days, it was revamped with ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Indivior’s restructuring plan is taking shape with initial headcount reductions to help move toward a more simplified organization. The first phase of the company’s “Indivior Action Agenda,” which ...

This retrospective study includes clinical case studies from four pregnant patients treated with monthly SUBLOCADE, postmarketing surveillance data covering more than five years, and a targeted ...